EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Drug-drug interactions of simnotrelvir/ritonavir: an open-label, fixed-sequence, two-period clinical trial

Pan-Pan Ye, Bu-Fan Yao, Yang Yang, Xin-Mei Yang, Qian Li, Lin-Lin Song, Ke-Guang Chen, Hai-Yan Zhou, Jin-Yi Shi, Ye-Hui Zhang, Fu-Rong Zhao, Zi-Jia Guo und 6 weitere

Clinical Microbiology and Infection · 2025

DOI: 10.1016/j.cmi.2024.09.007 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Microbiology and Infection, 2025. Verfasst von Pan-Pan Ye und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shando…. Hauptthemen laut MEDLINE: Drug Interactions, Ritonavir, Rifampin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong University, Taishan Scholar Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Simnotrelvir is a small-molecule highly specific 3C-like protease inhibitor for anti-SARS-CoV-2 and was approved as a combination drug with ritonavir (simnotrelvir/ritonavir) in China. Simnotrelvir is a substrate of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), and a weak inhibitor of CYP3A. Ritonavir is a substrate and inhibitor of CYP3A and an inhibitor of P-gp. Hence, the drug-drug interaction potential of simnotrelvir/ritonavir should be investigated. METHODS: This drug-drug interaction study was an open-label, fixed-sequence, two-period phase I clinical trial in Chinese healthy adult subjects, divided into three cohorts, including simnotrelvir/ritonavir co-administrated with a strong CYP3A and P-gp inhibitor (itraconazole) and inducer (rifampicin), and with a specific CYP3A substrate (midazolam). RESULTS: The results demonstrated that compared with administration of simnotrelvir/ritonavir alone, the co-administration with itraconazole increased the geometric least-square mean ratio (GMR) of the expose (area under the plasma concentration-time curve from time zero to the lowest detectable plasma concentration [AUC0-t]) of simnotrelvir by 25% (GMR 125%, 90% CI 114-137%), whereas co-administration with rifampicin significantly decreased the AUC0-t of simnotrelvir by 81.5% (GMR 18.5%, 90% CI 16.4-20.9%). Notably, simnotrelvir/ritonavir increased the AUC0-t of midazolam by 16.69-fold (GMR 1769%, 90% CI 1551-2018%). The co-administration of simnotrelvir/ritonavir and rifampicin caused the increased amount and severity of treatment-emergent adverse events, especially hepatotoxicity. DISCUSSION: The co-administration of simnotrelvir/ritonavir with CYP3A and P-gp inhibitors can be safely used, whereas the co-administration with CYP3A and P-gp strong inducer should be avoided to minimize the risk of under-exposure. Co-administration of midazolam with simnotrelvir/ritonavir increased systemic exposure of midazolam. CLINICALTRIALS: gov Identifier: NCT05665647.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsRitonavirRifampinHumansAdultMaleFemaleYoung AdultCytochrome P-450 CYP3A InhibitorsItraconazoleCytochrome P-450 CYP3AMidazolamAntiviral AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Middle AgedDrug CombinationsCOVID-19 Drug Treatment

Stichwörter der Autor:innen

Drug-drug interactionHealthy subjectsPharmacokineticsSafetySimnotrelvir

Substanzen

RitonavirRifampinCytochrome P-450 CYP3A InhibitorsItraconazoleCytochrome P-450 CYP3AMidazolamAntiviral AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Drug Combinations

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Devel…
  • Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China; Simcere Zaiming Pharmaceutical Co. Ltd., Nanjing, China.
  • State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China; Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing, China.

Förderung

  • Shandong University
  • Taishan Scholar Foundation of Shandong Province

Zitieren

APA

Ye, P. P., Yao, B. F., Yang, Y., Yang, X. M., Li, Q., Song, L. L., Chen, K. G., Zhou, H. Y., Shi, J. Y., Zhang, Y. H., Zhao, F. R., Guo, Z. J., Xu, S. S., Chen, J., Goh, A. H., Zhu, S. W., Zheng, Y., & Zhao, W. (2025). Drug-drug interactions of simnotrelvir/ritonavir: an open-label, fixed-sequence, two-period clinical trial. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2024.09.007

Vancouver

Ye PP, Yao BF, Yang Y, Yang XM, Li Q, Song LL, et al. Drug-drug interactions of simnotrelvir/ritonavir: an open-label, fixed-sequence, two-period clinical trial. Clinical Microbiology and Infection. 2025. doi:10.1016/j.cmi.2024.09.007

BibTeX
@article{Ye2025,
  author = {Ye, Pan-Pan and Yao, Bu-Fan and Yang, Yang and Yang, Xin-Mei and Li, Qian and Song, Lin-Lin and Chen, Ke-Guang and Zhou, Hai-Yan and Shi, Jin-Yi and Zhang, Ye-Hui and Zhao, Fu-Rong and Guo, Zi-Jia and Xu, Shan-Sen and Chen, Jia and Goh, Aik Han and Zhu, Shun-Wei and Zheng, Yi and Zhao, Wei},
  title = {Drug-drug interactions of simnotrelvir/ritonavir: an open-label, fixed-sequence, two-period clinical trial},
  journal = {Clinical Microbiology and Infection},
  year = {2025},
  doi = {10.1016/j.cmi.2024.09.007}
}
Kostenlos starten →